1
|
Design of experiment (DoE)-based formulation design of bepotastine sustained-release tablet and in vitro-in vivo pharmacokinetic correlation. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2023. [DOI: 10.1007/s40005-023-00611-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
2
|
Quality by Design (QbD) application for the pharmaceutical development process. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2022. [DOI: 10.1007/s40005-022-00575-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
3
|
Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach. Pharmaceutics 2022; 14:pharmaceutics14061219. [PMID: 35745792 PMCID: PMC9228348 DOI: 10.3390/pharmaceutics14061219] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Revised: 05/27/2022] [Accepted: 06/06/2022] [Indexed: 12/01/2022] Open
Abstract
We aimed to develop nafamostat mesylate immediate-release tablets for the treatment of COVID-19 through drug repositioning studies of nafamostat mesylate injection. Nafamostat mesylate is a serine protease inhibitor known to inhibit the activity of the transmembrane protease, serine 2 enzyme that affects the penetration of the COVID-19 virus, thereby preventing the binding of the angiotensin-converting enzyme 2 receptor in vivo and the spike protein of the COVID-19 virus. The formulation was selected through a stability study after manufacturing by a wet granulation process and a direct tableting process to develop a stable nafamostat mesylate immediate-release tablet. Formulation issues for the selected processes were addressed using the design of experiments and quality-by-design approaches. The dissolution rate of the developed tablet was confirmed to be >90% within 30 min in the four major dissolutions, except in the pH 6.8 dissolution medium. Additionally, an in vivo pharmacokinetic study was performed in monkeys, and the pharmacokinetic profiles of nafamostat injections, oral solutions, and tablets were compared. The half-life during oral administration was confirmed to be significantly longer than the reported literature value of 8 min, and the bioavailability of the tablet was approximately 25% higher than that of the oral solution.
Collapse
|
4
|
Quality by Design: A Suitable Methodology in Industrial Pharmacy for Costa Rican Universities. Sci Pharm 2022. [DOI: 10.3390/scipharm90020034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
This review aims to present the Quality by Design (QbD) model as a suitable methodology to perform research in the academic Costa Rican institutions that teach Pharmacy. Pubmed, Science Direct, and Google Scholar databases were screened for original research papers and review papers published not more than ten years ago. Institutional repositories from the different universities were reviewed as well. The QbD model stands out as a great methodology for carrying out research projects regarding Pharmaceutical Sciences, but especially for Industrial Pharmacy, where it has contributed in terms of formulation development, manufacturing, and quality control. Academic research based on this model enables the training and development of practical, scientific, and leadership skills in Industrial Pharmacy students. The generated knowledge can be shared in classrooms, which represents an ideal environment to communicate research results and to foster collaborative work between researchers, professors, and students. Moreover, research performed through a QbD approach increases the confidence shown by the industrial sector and health regulatory authorities in the quality of the research, products, and knowledge that are developed and created in an Academy. As a result, the implementation of the model has allowed the creation, transfer, and materialization of knowledge from the Costa Rican Academy to different local pharmaceutical industries.
Collapse
|
5
|
Studies on Preformulation and Formulation of JIN-001 Liquisolid Tablet with Enhanced Solubility. Pharmaceuticals (Basel) 2022; 15:ph15040412. [PMID: 35455409 PMCID: PMC9030333 DOI: 10.3390/ph15040412] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Revised: 03/22/2022] [Accepted: 03/25/2022] [Indexed: 01/27/2023] Open
Abstract
This study aimed to develop a heat shock protein 90 (Hsp90) inhibitor liquisolid tablet with improved solubility to overcome low bioavailability issues. As an active pharmaceutical ingredient (API), JIN-001, a novel Hsp90 inhibitor, was reported to have substantial in vitro antiproliferative and in vivo antitumor activity; however, JIN-001 was a crystalline solid with very low solubility in an aqueous solution, and therefore, Capryol 90, which has excellent solubilization ability, was selected as an optimal liquid vehicle based on solubility studies. JIN-001 liquisolid (JLS) powder was successfully prepared by dissolving JIN-001 in Capryol 90 and mixing colloidal silicon dioxide (CSD) used as an oil adsorption agent. The prepared JLS was confirmed to be amorphous. Based on the result of the solubility test of JLS, compared to JIN-001, the solubility of the former was significantly improved in all solvents regardless of pH. JLS tablets were prepared through wet granulation using JIN-001 and stable excipients based on the compatibility test. The developed JLS tablet significantly increased the drug release rate in all tested solutions; however, the liquisolid method had no significant effect on bioavailability in the pharmacokinetics study in beagle dogs. In conclusion, the liquisolid system influenced the solubility and dissolution rate of JIN-001.
Collapse
|
6
|
Sarisaltik-Yasin D, Uslu A, Uyar E, Erdinc M, Teksin ZS. QbD Application for a Fixed-Dose Combination with Biowaiver Potential: Evaluations of In Vitro and In Vivo Applications. J Pharm Innov 2022. [DOI: 10.1007/s12247-022-09633-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Kim JE, Park YJ. QbD Consideration for Developing a Double-Layered Tablet into a Single-Layered Tablet with Telmisartan and Amlodipine. Pharmaceutics 2022; 14:pharmaceutics14020377. [PMID: 35214109 PMCID: PMC8874924 DOI: 10.3390/pharmaceutics14020377] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 01/22/2022] [Accepted: 01/27/2022] [Indexed: 12/10/2022] Open
Abstract
The aim of this study was to develop a single-layered version of commercially available Twynstar® (Telmisartan + Amlodipine) double-layered tablets to improve the dosing convenience. A quality-by-design approach was applied to develop the single-layered version. To evaluate the range and cause of risks for a single-layered tablet in the formulation design research, we used the tools of the risk assessment, initial risk assessment of preliminary hazard analysis and main risk assessment of failure mode and effect analysis to determine the parameters affecting formulation, drug dissolution, and impurities. The critical material attributes were the stabilizer and disintegrant, and the critical process parameters were the wet granulation and tableting process. The optimal range of the design space was determined using the central composite design in the wet granulation and tablet compression processes. The stabilizer, kneading time, and disintegrant of the wet granulation were identified as X values affecting Y values. The compression force and turret speed in the tablet compression were identified as X values affecting Y values. After deciding on the design space with the deduced Y values, the single-layered tablets were formulated, and their dissolution patterns were compared with that of the double-layered tablet. The selected quality-by-design (QbD) approach single-layered tablet formulated using design space were found to be bioequivalent to the Twynstar® double-layered tablets. Hence, the development of single-layered tablets with two API using the QbD approach could improve the medication compliance of patients and could be used as a platform to overcome time-consuming and excessive costs and the technical and commercial limitations related to various multi-layered tablets.
Collapse
Affiliation(s)
- Joo-Eun Kim
- Department of Pharmaceutical Engineering, Catholic University of Daegu, Hayang-Ro 13-13, Hayang-Eup, Gyeongsan City 38430, Gyeongbuk, Korea;
| | - Young-Joon Park
- College of Pharmacy, Ajou University, Worldcup-ro 206, Yeongtong-gu, Suwon-si 16499, Korea
- Correspondence: ; Tel.: +82-53-850-2561 (J.-E.K.); +82-31-219-3493 (Y.-J.P.)
| |
Collapse
|
8
|
Lee SH, Kim JE. Quality by Design Applied Development of Immediate-Release Rabeprazole Sodium Dry-Coated Tablet. Pharmaceutics 2021; 13:pharmaceutics13020259. [PMID: 33673019 PMCID: PMC7918775 DOI: 10.3390/pharmaceutics13020259] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 02/07/2021] [Accepted: 02/08/2021] [Indexed: 11/30/2022] Open
Abstract
The aim of this study was to develop immediate-release oral rabeprazole sodium tablets with rapid efficacy and gastric stability for the treatment of gastroesophageal reflux disease. Rabeprazole sodium is a commonly prescribed proton pump inhibitor; however, it is extremely unstable and degrades in acidic environments. Hence, it has been manufactured and supplied only in enteric-coated tablet form, while immediate-release (IR) formulations for this drug are very limited. In this study, we applied the quality by design (QbD) approach to formulate and optimize an IR dry-coated tablet containing rabeprazole sodium as an inner core with an outer sodium bicarbonate layer to stabilize the active pharmaceutical ingredient at gastric pH. We also investigated the stability of the pharmaceutical dosage form and its pharmacokinetic profile. The results show that the developed tablets are stable for approximately 12 months and have a high dissolution rate, greater than or equal to 90% at 30 min. Further, in vivo beagle pharmacokinetics confirmed that the newly developed IR tablet had an AUCt which is bioequivalent to the existing delayed-release rabeprazole tablet; however, its Tmax was 0.5 h, which is up to seven times faster than that of the existing tablet. Moreover, the IR tablet was found to immediately absorb in the stomach. Hence, the development of IR tablets can be used as a platform to overcome the technical and commercial limitations currently associated with various proton pump inhibitors used to treat patients with gastroesophageal reflux disease that require immediate therapeutic relief.
Collapse
|
9
|
Muta T, Parikh A, Kathawala K, Haidari H, Song Y, Thomas J, Garg S. Quality-by-Design Approach for the Development of Nano-Sized Tea Tree Oil Formulation-Impregnated Biocompatible Gel with Antimicrobial Properties. Pharmaceutics 2020; 12:E1091. [PMID: 33202841 PMCID: PMC7698170 DOI: 10.3390/pharmaceutics12111091] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 11/05/2020] [Accepted: 11/07/2020] [Indexed: 01/30/2023] Open
Abstract
Despite the promising properties of tea tree oil (TTO) as potential therapeutics for several superficial skin conditions, certain limitations such as physical instability and skin irritation have restricted its widespread use. This study focuses on developing a rationally designed lipid-based nanoformulation (TTO-LNF) in accordance with the US Food and Drug Administration standard using a well-recognized quality-by-design (QbD) approach. Using a mixture experimental design, TTO-LNF has been optimized with 5% TTO, 10% surfactant, 5% co-surfactant, and 80% water, which showed a 14.4 ± 4.4 nm droplet size and 0.03 ± 0.01 polydispersity index (PDI). To ease the topical administration, the TTO-LNF gel formulation was further developed using xanthan gum to achieve the desired viscosity and form a gel. The in vitro antibacterial tests of TTO-LNF showed promising inhibitory effects toward both Gram-negative and Gram-positive bacteria. In fact, a complete growth inhibition of S. epidermidis was observed when exposed to TTO-LNF and TTO-LNF gel for 24 h, showing better activity than antibiotic kanamycin (25 µg/mL). Additionally, the in vitro release study showed a sustained release profile with a 50% release in 24 h, which could be beneficial to reduce the toxicity and thereby improve the therapeutic efficacy for long-acting applications. Furthermore, the formulations were remarkably stable at 40 °C/75% Relative humidity (RH) for at least 4 weeks. Therefore, this study presents a promising strategy to develop a biocompatible and stable formulation that can be used for the topical treatment of skin infections.
Collapse
Affiliation(s)
- Thabata Muta
- Pharmaceutical Innovation and Development Group (PIDG), UniSA Clinical & Health Science, University of South Australia, City West Campus, North Terrace, Adelaide, SA 5000, Australia; (T.M.); (A.P.); (K.K.); (H.H.); (Y.S.)
| | - Ankit Parikh
- Pharmaceutical Innovation and Development Group (PIDG), UniSA Clinical & Health Science, University of South Australia, City West Campus, North Terrace, Adelaide, SA 5000, Australia; (T.M.); (A.P.); (K.K.); (H.H.); (Y.S.)
| | - Krishna Kathawala
- Pharmaceutical Innovation and Development Group (PIDG), UniSA Clinical & Health Science, University of South Australia, City West Campus, North Terrace, Adelaide, SA 5000, Australia; (T.M.); (A.P.); (K.K.); (H.H.); (Y.S.)
| | - Hanif Haidari
- Pharmaceutical Innovation and Development Group (PIDG), UniSA Clinical & Health Science, University of South Australia, City West Campus, North Terrace, Adelaide, SA 5000, Australia; (T.M.); (A.P.); (K.K.); (H.H.); (Y.S.)
| | - Yunmei Song
- Pharmaceutical Innovation and Development Group (PIDG), UniSA Clinical & Health Science, University of South Australia, City West Campus, North Terrace, Adelaide, SA 5000, Australia; (T.M.); (A.P.); (K.K.); (H.H.); (Y.S.)
| | - Jackson Thomas
- Faculty of Health, University of Canberra, Canberra, ACT 2617, Australia;
| | - Sanjay Garg
- Pharmaceutical Innovation and Development Group (PIDG), UniSA Clinical & Health Science, University of South Australia, City West Campus, North Terrace, Adelaide, SA 5000, Australia; (T.M.); (A.P.); (K.K.); (H.H.); (Y.S.)
| |
Collapse
|
10
|
Roy H, Nandi S, Pavani U, Lakshmi U, Reddy TS, Gayatri DVS. Optimization and Quality by Design Approach for Piroxicam Fast Dissolving Tablet Formulations Using Box-Behnken Design. CURRENT DRUG THERAPY 2020. [DOI: 10.2174/1574885514666190409102614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
The present study deals with the formulation and optimization of piroxicam
fast dissolving tablets and analyzes the impact of an independent variable while selecting the
optimized formulation utilizing Quality by Design (QbD) and Box-Behnken Design (BBD).
Methods:
Seventeen formulations were prepared by direct compression technique by altering the
proportion of cross carmellose sodium, spray dried lactose and hydro propyl methyl cellulose
(HPMC K4M). The BBD statistical technique was used to optimize formulations and correlate the
relationship among all the variables. Also, the powder mixture characteristics and tablet physiochemical
properties such as hardness, friability, drug content, Disintegration Time (DT) and dissolution
test were determined using 900 ml of 0.1N HCl (pH-1.2) at 37 ± 0.5°C.
Results:
Significant quadratic model and second order polynomial equations were established using
BBD. To find out the relationship between variables and responses, 3D response surface and 2D
contour plot was plotted. A perturbation graph was also plotted to identify the deviation of the variables
from the mean point. An optimized formula was prepared based on the predicted response and
the resulting responses were observed to be close with the predicted value.
Conclusion:
The optimized formulation with the desired parameter and formulation with variables
and responses can be obtained by BBD and could be used in the large experiment with the involvement
of a large number of variables and responses.
Collapse
Affiliation(s)
- Harekrishna Roy
- Department of Pharmaceutics, Nirmala College of Pharmacy, Mangalagiri, Guntur, Andhra Pradesh, 522503, India
| | - Sisir Nandi
- Department of Pharmaceutical Chemistry, Global Institute of Pharmaceutical Education and Research, Affiliated to Uttarakhand Technical University, Kashipur-244713, India
| | - Ungarala Pavani
- Department of Pharmaceutics, Nirmala College of Pharmacy, Mangalagiri, Guntur, Andhra Pradesh, 522503, India
| | - Uppuluri Lakshmi
- Department of Pharmaceutics, Nirmala College of Pharmacy, Mangalagiri, Guntur, Andhra Pradesh, 522503, India
| | - Tamma Saicharan Reddy
- Department of Pharmaceutics, Nirmala College of Pharmacy, Mangalagiri, Guntur, Andhra Pradesh, 522503, India
| | - Damarla Venkata Sri Gayatri
- Department of Pharmaceutics, Nirmala College of Pharmacy, Mangalagiri, Guntur, Andhra Pradesh, 522503, India
| |
Collapse
|
11
|
Pereira RR, Testi M, Rossi F, Silva Junior JOC, Ribeiro-Costa RM, Bettini R, Santi P, Padula C, Sonvico F. Ucuùba ( Virola surinamensis) Fat-Based Nanostructured Lipid Carriers for Nail Drug Delivery of Ketoconazole: Development and Optimization Using Box-Behnken Design. Pharmaceutics 2019; 11:pharmaceutics11060284. [PMID: 31212993 PMCID: PMC6630981 DOI: 10.3390/pharmaceutics11060284] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2019] [Revised: 06/10/2019] [Accepted: 06/11/2019] [Indexed: 12/17/2022] Open
Abstract
Ucuùba fat is fat obtained from a plant found in South America, mainly in Amazonian Brazil. Due to its biocompatibility and bioactivity, Ucuùba fat was used for the production of ketoconazole-loaded nanostructured lipid carriers (NLC) in view of an application for the treatment of onychomycosis and other persistent fungal infections. The development and optimization of Ucuùba fat-based NLC were performed using a Box-Behnken design of experiments. The independent variables were surfactant concentration (% w/v), liquid lipids concentration (% w/v), solid lipids concentration (% w/v), while the outputs of interest were particle size, polydispersity index (PDI) and drug encapsulation efficiency (EE). Ucuùba fat-based NLC were produced and the process was optimized by the development of a predictive mathematical model. Applying the model, two formulations with pre-determined particle size, i.e., 30 and 85 nm, were produced for further evaluation. The optimized formulations were characterized and showed particle size in agreement to the predicted value, i.e., 33.6 nm and 74.6 nm, respectively. The optimized formulations were also characterized using multiple techniques in order to investigate the solid state of drug and excipients (DSC and XRD), particle morphology (TEM), drug release and interactions between the formulation components (FTIR). Furthermore, particle size, surface charge and drug loading efficiency of the formulations were studied during a one-month stability study and did not show evidence of significant modification.
Collapse
Affiliation(s)
- Rayanne R Pereira
- Pharmaceutical Sciences Faculty, Federal University of Para, 66075-110 Belem, Brazil.
- Food and Drug Department, University of Parma, 43124 Parma, Italy.
| | - Matteo Testi
- Food and Drug Department, University of Parma, 43124 Parma, Italy.
| | - Francesca Rossi
- Institute of Materials for Electronics and Magnetism (IMEM), CNR-Italian National Research Council, Parco Area delle Scienze 37/A, 43124 Parma, Italy.
| | - Jose O C Silva Junior
- Pharmaceutical Sciences Faculty, Federal University of Para, 66075-110 Belem, Brazil.
| | | | - Ruggero Bettini
- Food and Drug Department, University of Parma, 43124 Parma, Italy.
- Biopharmanet-TEC, University of Parma, 43124 Parma, Italy.
| | - Patrizia Santi
- Food and Drug Department, University of Parma, 43124 Parma, Italy.
- Biopharmanet-TEC, University of Parma, 43124 Parma, Italy.
| | - Cristina Padula
- Food and Drug Department, University of Parma, 43124 Parma, Italy.
| | - Fabio Sonvico
- Food and Drug Department, University of Parma, 43124 Parma, Italy.
- Biopharmanet-TEC, University of Parma, 43124 Parma, Italy.
| |
Collapse
|